NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis $0.06 -0.02 (-25.13%) Closing price 11/19/2026 04:00 PM EasternExtended Trading$0.05 0.00 (-6.15%) As of 09:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Vivos Therapeutics Stock (NASDAQ:VVOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vivos Therapeutics alerts:Sign Up Key Stats Today's Range$0.05▼$0.0750-Day Range$0.06▼$0.1852-Week Range$0.05▼$2.69Volume4.43 million shsAverage Volume1.08 million shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice Target$2.80Consensus RatingHold Company Overview Vivos Therapeutics is a medical technology company focused on treatments for sleep-disordered breathing, including obstructive sleep apnea. The company works with dental providers to offer non-surgical approaches intended to improve patients’ airways and breathing during sleep. Its Vivos System combines proprietary oral appliances with treatment protocols used by trained dental professionals. The company also provides education and support to providers who offer its therapies. Based in Littleton, Colorado, Vivos primarily serves patients through a network of participating dental practices. Its approach is designed for use in dental settings and may involve collaboration with other healthcare professionals.AI Generated. May Contain Errors. Read More Vivos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreVVOS MarketRank™: 2.25196091922 of 5 starsVivos Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingVivos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVivos Therapeutics has a consensus price target of $2.80, representing about 4,820.9% upside from its current price of $0.06.Amount of Analyst CoverageVivos Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Vivos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vivos Therapeutics are expected to grow in the coming year, from ($1.30) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vivos Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vivos Therapeutics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.47% of the float of Vivos Therapeutics has been sold short.Short Interest Ratio / Days to CoverVivos Therapeutics has a short interest ratio ("days to cover") of 0.25, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos Therapeutics has recently increased by 30.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivos Therapeutics does not currently pay a dividend.Dividend GrowthVivos Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.74 News SentimentVivos Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Vivos Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for VVOS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Vivos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.40% of the stock of Vivos Therapeutics is held by insiders.Percentage Held by Institutions26.35% of the stock of Vivos Therapeutics is held by institutions.Read more about Vivos Therapeutics' insider trading history. Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VVOS Stock News HeadlinesMerit Medical Systems (NASDAQ:MMSI) vs. Vivos Therapeutics (NASDAQ:VVOS) Financial AnalysisNovember 18 at 3:58 AM | americanbankingnews.comVivos outlines payer renegotiations targeting ~$3.8M annual lift while aiming for positive operating cash flow in early 2027November 17 at 5:50 PM | seekingalpha.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 20 at 1:00 AM | American Alternative (Ad)Vivos Therapeutics, Inc. (VVOS) Q3 2026 Earnings Call Prepared Remarks TranscriptNovember 17 at 5:50 PM | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue EstimatesNovember 16, 2026 | finance.yahoo.comVivos Therapeutics Reports 24% Sequential Revenue Growth in Q3 2026 and Regains Nasdaq Equity ComplianceNovember 16, 2026 | quiverquant.comQVivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational UpdateNovember 16, 2026 | globenewswire.comCORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell TestOctober 29, 2026 | theglobeandmail.comSee More Headlines VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed this year? Vivos Therapeutics' stock was trading at $2.03 at the beginning of 2026. Since then, VVOS stock has decreased by 97.2% and is now trading at $0.0569. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its quarterly earnings data on Monday, November, 16th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.23. The firm earned $6.41 million during the quarter, compared to the consensus estimate of $5.48 million. Vivos Therapeutics had a negative net margin of 107.36% and a negative trailing twelve-month return on equity of 2,325.64%. Read the conference call transcript. When did Vivos Therapeutics' stock split? Shares of Vivos Therapeutics reverse split on Friday, October 27th 2023.The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $21 million in an IPO on Thursday, December 10th 2020. The company issued 3,500,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vivos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Advanced Micro Devices (AMD), SoFi Technologies (SOFI), Tesla (TSLA), Alibaba Group (BABA), BigBear.ai (BBAI), Chevron (CVX) and Johnson & Johnson (JNJ). Company Calendar Last Earnings11/16/2026Today11/20/2026AGM 202612/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 VVOS's financial health is in the Red zone, according to TradeSmith. VVOS has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:VVOS CIK1716166 Webwww.vivos.com Phone866-908-4867FaxN/AEmployees268Year Founded2013Price Target and Rating Average Price Target for Vivos Therapeutics$2.80 High Price Target$3.10 Low Price Target$2.50 Potential Upside/Downside+4,820.9%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.17 million Net Margins-107.36% Pretax Margin-108.11% Return on Equity-2,325.64% Return on Assets-90.72% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.21 Sales & Book Value Annual Sales$17.44 million Price / Sales0.07 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-0.81Miscellaneous Outstanding Shares20,120,000Free Float19,836,000Market Cap$1.14 million OptionableOptionable Beta6.37 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:VVOS) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.